BU-NOT-SET

CONTACT US
Overcoming oncolytic virus obstacles with the help of a CDMO partnership
  • Biologics
oncolytic virus
Insight
Webinar: Beyond borders: Navigating global scale-up for viral-based therapies
  • Biologics
webinar
Webinar
Choosing the right container for your sterile drug product
  • Drug product
eBook: How a CDMO partner helps choose the right container for sterile drug products
eBook
Cell and virus banking in OV development and manufacturing
  • Biologics
Cell and virus banking
White paper
Overcoming technical transfer challenges in virotherapy manufacturing
  • Biologics
virotherapy
Insight
Flexibility in gene therapy: Adapting to the unique gene therapy demands
  • Biologics
gene therapy
eBook
Webinar: An optimised Plasmid DNA platform
  • Biologics
Plasmid DNA
Webinar
The future of oral solid dose formulations
  • Drug substance
  • Industry trends
oral solid dose
Insight
Trends and challenges to impact the OSD space in 2024 and beyond
  • Industry trends
OSD
Insight
Insight
  • Industry trends
Brexit: What’s next for UK pharma?
Insight
  • Drug substance
Navigating approval filings choppy international waters
Insight
  • Drug substance
Regulatory requirements for drug substances
Insight
  • Analytical chemistry
The QbD approach: Key advantages in clinical and commercial phases
Report
  • Sustainability
Sustainability report 2020
Poster
  • Drug substance
Recipharm and Oncopeptides: Successful collaboration in the development of melflufen, a peptidase-potentiated alkylating agent in clinical trials
Fact sheet
  • Analytical chemistry
Recipharm Analytical Solutions™
Fact sheet
  • Analytical chemistry
Impurity identification
Fact sheet
  • Analytical chemistry
Stability studies